Behind moves to regulate breastmilk trade lies the threat of a corporate takeover

Originally published on theconversation.com

Romanova Anna/Shutterstock

The European Union is preparing to harmonise regulations governing the trade in human milk, which sounds like a good thing. But it won’t be if it sidelines breastfeeding or makes informal human-to-human milk exchanges more difficult.

Women and their families have exchanged human milk informally (including for money) throughout history, and still do.

Until a century ago human milk was mainly delivered in person, breast-to-child, by friends, relatives or wet nurses if mothers couldn’t provide it.

Woman buying milk from nurse at counter, 1939.
AP-HP Archives

As the paediatric profession developed, hospitals in Europe and the United States took over the process and began administering human milk by bottles, at first filled by volunteers, and later, in the lead-up to the second world war, by paid donors.

Higher women’s wages after the war made paying donors financially prohibitive, and most countries moved closer to a “gift economy” in which payment for products such as human milk and blood was seen as inappropriate, alongside a growing commercial market for formula and powder derived from cows milk.

Donor milk collected by charities and non-profit organisations from screened donors is mostly pasteurised and tested to minimise risks of disease.

Biotech discovers breast milk

Things changed in 1999 when an American company, Prolacta, developed human milk-based products for fortifying breast milk fed to premature infants.

At first Prolacta didn’t pay donors, but it now pays about US$4 per 100ml for milk it uses to make products that sell for up to US$250 per 100 ml.


Prolacta human milk products

In 2015 a not-for-profit Utah-based company, Ambrosia Labs established clinics in Cambodia to collect milk for exporting to the United States.

After the United Nations Children’s Fund condemned the practice saying breast milk could be considered “human tissue” the Cambodian government banned it. Some mothers despaired at losing crucial income.



Read more:
Without better regulation, the market for breast milk will exploit mothers

A few years later in 2017 an Australian-Indian company Neolacta, was granted permission to sell milk collected from Indian mothers in Australia.

In 2019 a related company, NeoKare, established a “state-of-the-art” plant in Europe making freeze-dried fortifier sourced from UK donors.

These human milk product manufacturers are competing with cow-sourced product manufacturers such as Nestle and might soon be competing with start-ups growing new products that mimic human milk.

Industry backs new regulation

The harmonisation being considered by the European Union would extend to human milk the rules that already govern trade in blood, tissues and cells.

Some member states in the European Union already apply tissue and cell rules to human milk, others apply food legislation, and at least 11 don’t regulate it at all.

Australian regulators will be watching closely, because Australian states and territories have similarly diverse rules.

That formula companies are backing the idea provides cause for concern.

But it’s women who matter

Health authorities have already expressed disquiet about commerce-free internet-based milk sharing. The proposal would give them greater powers to act against it.

If these powers were applied heavily they could shut down the generally safe and self-regulated human-to-human trade.

And advancing the medical market for human milk products might delay the advances in social and employment protection policies needed to support breastfeeding at work, at home and in public.


Australian Breastfeeding Association

Human milk is not simply a homogenised “commodity crop in a bottle”.

Breastfeeding creates connections that are important for women’s health and wellbeing and for their babies.

Ironically, where governments fail to adequately protect, promote and support breastfeeding, mothers are often forced to turn to commercial formula for a quick fix.

The proposals as drafted pay scant regard to the United Nations human rights commissioner’s view that “states should do more to support and protect breastfeeding, and end inappropriate marketing of breast-milk substitutes”.

A truly comprehensive set of laws would include protection from marketing and biomedical experiments and allow suitable recompense for donors. Serological testing would be easily available to donors along with guidance to support milk sharing outside of medical facilities.



Read more:
The rise of commercial milk formulas matters for women and children

Such comprehensive laws would impose levies on commercial substitutes in order to fund better breastfeeding support in maternity and newborn facilities.

They would have at their centre the needs and rights of women, who are both the main providers of human milk and (on their children’s behalf) its biggest users.

Julie P. Smith receives funding from the Australian Research Council under an ARC Future Fellowship, for her research on measurement, understanding, and policy regulatory approaches to emerging markets and trade in mothers’ milk (FT140101260). She has previously received funding from the World Health Organization and the Australian Department of Health for research consultancies on marketing of baby foods and breastfeeding policy. She is also a volunteer breastfeeding counsellor, community educator, and honorary member of the Australian Breastfeeding Association, and an associate member of the Lactation Consultants Association of Australia and New Zealand.

Dr. Tanya M. Cassidy receives funding from the Irish Research Council for her research entitled “Parenting in the Pandemic.” She also received funding from the Irish Health Research Board, the Fulbright Commission in Ireland, and the European Commission. She volunteers as an ethics advisor to the UK Association of Milk Banking (UKAMB) Scientific Advisory Board. Also, she volunteers her expertise to parent groups across Europe.

Mathilde Cohen does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Leave a comment

Your email address will not be published. Required fields are marked *